Navigation Links
Undisclosed in Medical News

Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation

DOYLESTOWN, Pa., May 19 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY ) , www.quigleyco.com , today announced that it has uncovered an improper financial relationship between Ted Karkus and the Company's Quigley Pharma, Inc. wholly-owned subsidiary COO, Dr. Richard A. ...

Coffee king American Flavor 3 in 1 Coffee mix contains undisclosed milk protein

Ottawa - The Canadian Food Inspection Agency (CFIA) has issued a warning for those who are allergic to milk, to avoid consumption of the Coffee king American Flavor// 3 in 1 Coffee mix brand. This product is said to contain a milk protein ingredient which the manufacturers have not disclosed on the...

Allergy Alarm: Sam's Choice Milk Chocolate Turns Bitter with Undisclosed 'Nuts'

Brach's Confections, Inc. of Dallas, Texas are tough nuts to crack, indeed. Presently, they have withdrawn a batch of production of Sam's Choice Belgian Milk Chocolate Bars,// due to the presence of undeclared almonds. This is a precautionary measure to ensure safety for all those who are allergic ...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Ned Russell Joins Saatchi & Saatchi Wellness

...nth SSW was awarded the Durex account following a review. In addition, the agency has picked up four additional assignments in health and wellness for undisclosed new products. "Saatchi & Saatchi Wellness is an agency with a distinct point of view and focus - marketing well-being is a strong differ...

Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation

...xclusivity. Caraco will take over the commercialization and sale of several products from Forest's Inwood business. Caraco will pay Forest an undisclosed advance against royalties and royalties on net sales of these products. In exchange for an upfront payment (and royalties but only if the tech...

Health Club Media Network Acquires the Alloy Fitness Network

...ational brands in health clubs, announced today its acquisition of the Alloy Fitness Network from Alloy Media + Marketing. The transaction includes an undisclosed cash sum plus certain future contingent payments. The Alloy Fitness Network includes contractual agreements for media panel placements in over 70...

Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics

...ll address inflammatory and autoimmune diseases. Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone paym...preclinical development by Catalyst of Alterase(TM) therapeutics against an undisclosed target, with an option to expand the agreement to include a second target. ...

Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community

...mmunity working to legitimize the validity of patents. Community members - whom Article One calls Advisors - have an opportunity to send in previously undisclosed evidence of patent validity. By tapping the unique knowledge and referral networks of our Advisors, this evidence known as prior art can be discovered...

KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter

...and distribute certain of KV's proprietary technologies and products in its territories, including the European Union. KV Pharmaceutical will receive undisclosed milestones and royalties for products developed under the terms of the agreement. The agreement also provides for the development of additional p...
Undisclosed in Medical Technology

EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health

...d marketing enzymes and other proteins for the chemical industry, announced today that it has achieved an important milestone in the development of an undisclosed protein for Lohmann Animal Health (LAH), a leading provider of feed components and vaccines for farm animals. This achievement triggered a milestone p...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

...body and will thereafter assume responsibility for further clinical development and commercialisation on a worldwide basis. OBT will receive an undisclosed upfront payment and will be eligible for up to a total of $370m (GBP244m) upon the achievement of specified discovery, development, regulatory and com...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

... to be initiated in the first half of 2009. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee

...dates TG-C and TG-B, developed for the regeneration of cartilage and bone, respectively. Under the terms of the agreement, TissueGene has received an undisclosed up-front payment and will receive on-going royalty payments based upon future sales. TissueGene is currently completing Phase I clinical trials in th...

Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

...payment to Ambrx, and Ambrx is eligible to receive undisclosed clinical, regulatory and commercial milestone paym...ucts resulting from this collaboration, as well as undisclosed royalties on the associated worldwide net sales. A... as profit. In addition, Merck Serono will make an undisclosed equity investment in Ambrx. Additional terms of t...
Undisclosed in Biological News

Chantix side effects no worse with depression history

...e trial detected only one serious psychiatric event involving suicidal thoughts and requiring hospitalization. It was in a person who had a previously undisclosed history of bipolar disorder. ...

Re-analysis of cigarettes confirms tobacco companies increased addictive nicotine 11 percent

... smoking each year. In conclusion, according to the HSPH researchers, the extended analysis of MDPH data has demonstrated its potential to reveal undisclosed hazards to human health. They suggest that MDPH amend its unique reporting requirements to include more information about cigarette and smokeless toba...
Undisclosed in Biological Technology

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based fully...

Micromet Closes $80.5 Million Public Offering of Common Stock

...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet Announces Pricing of Public Offering of Common Stock

...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet Announces Public Offering of Common Stock

...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA

...nts Merck KGaA non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT((R)) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other d...

Micromet Added to Russell 3000 Index

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. F...

AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS

...seases that have so far seemed unsuitable for treatment by vaccination, but that represent markets worth billions. Vaccine candidates for four further undisclosed chronic diseases are currently being developed by AFFiRiS AG. Asked about the success story of AFFiRiS AG and the current award, Andreas Höfle...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...
Other Tags
(Date:11/22/2014)... (PRWEB) November 22, 2014 Hastings and ... decades of experience announces providing clients with the option ... firm offers clients a flexible, intuitive and easy to ... with having access to Google + allows clients to ... to make a more informed decision when retaining an ...
(Date:11/22/2014)... FL (PRWEB) November 22, 2014 ... Innovations are pleased to announce that Ashley Lombardo ... Thanksgiving #PayItForward contest. , Ms. Lombardo entered friend ... Kitchen Innovations. She wrote of how her friend is ... daughters as a single mom. Despite medical bills piling ...
(Date:11/22/2014)... Boulder, CO (PRWEB) November 22, 2014 ... on growth equity investments in the consumer brand ... LLC. The investment will be used to help ... new product pipeline rollout, particularly its proprietary apparel ... Suslow will join BackJoy’s Board of Directors. , ...
(Date:11/22/2014)... Aliso Viejo, California (PRWEB) November 22, 2014 ... have announced a new plugin entitled FCPX 3D Model bringing ... , “FCPX 3D Model allows users to add obj files ... of Pixel Film Studios. “Blurring the line between professional and ... FCPX3D Model from Pixel Film Studios allows Final Cut Pro ...
(Date:11/22/2014)... Wright & Schulte LLC reports that six ... been scheduled between October 2016 and April 2017 in ... District Judge Matthew F. Kennelly, who is overseeing the ... on November 6, 2014 that outlined the trial schedule ... and other activities in preparation for the bellwether jury ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
(Date:11/3/2014)... 3, 2014 Research and Markets has ... - Technologies, Markets and Companies" to their offering. ... and methods, which have already started to play an important ... is replacing the old fashioned bone marrow transplants. Role of ... bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
Other Contents